Researchers found that combining liver transplantation and coronary artery bypass grafting is a safe approach for patients with severe coronary artery disease and end-stage liver disease. The procedure's success depends on careful multidisciplinary evaluation, coordination, and graft selection.
A recent study published in Hepatology found that occult HBV infection is prevalent in adult hemodialysis patients, with a rate four to five times higher than standard HBsAg testing. The majority of infections were associated with low viral loads and the sG145R-mutant.
Researchers demonstrate that long-term maintenance therapy with peginterferon alfa-2b can prevent or delay the progression of hepatitis C, reducing the risk of liver damage by half. A new antiviral agent, NM283, also shows promising activity against genotype 1 HCV, offering hope for future therapies.
A new study finds that combining Pegasys with ribavirin reduces hepatitis C viral levels more effectively than Peg-Intron, a promising development in treating the virus. The study's lead investigator hopes that the findings will inform the design of better drugs to combat the infection.
A study of nearly 400 African-American patients found that weight-based REBETOL dosing with PEG-INTRON improved viral clearance and reduced relapse rates compared to a flat dose. The treatment showed promise in improving outcomes for this patient population, which has historically had lower response rates to hepatitis C therapy.
A study has identified two distinct subclasses of liver cancer with differing survival rates, providing new molecular insight into the pathogenesis of hepatocellular carcinoma. The findings suggest that gene expression profiles can accurately predict patient survival and may lead to the development of more targeted therapies.
A study found that patients who received liver transplants from living donors are more likely to experience severe Hepatitis C recurrence. The research, led by Xavier Forns, investigated the effect of donor life status on HCV patient outcomes and discovered a significant association between living donor transplantation and severe disea...
Research on hepatitis C patients after liver transplantation found that 10-year outcomes are similar to those for other indications, but risk of recurrence and failure increases over time. Factors such as donor and recipient age, viral load, and CMV antibodies can predict transplant success.
A study conducted at the Mayo Clinic found that gastrointestinal endoscopy assistants, trained under supervision, can perform large-volume paracenteses safely and efficiently, with a median procedure time of two hours. The practice has been shown to save physician time without increasing patient risk.
Researchers discovered that inflammatory genes are activated and control bile duct obstruction in biliary atresia, a disease affecting up to 50% of children undergoing liver transplants. Blocking these inflammatory signals may prevent disease progression and increase long-term survival.
Experts disagree on acetaminophen's safety; William M. Lee advocates for stricter regulation to reduce overdoses, while Barry H. Rumack suggests therapeutic doses are safe and most cases may be intentional overdose attempts.
The Mayo Clinic discovery sheds light on the cellular mechanisms behind Non-Alcoholic Fatty Liver Disease (NAFLD), a growing global problem related to affluence and diet. Early signs include accumulation of fat in the liver, inflammation, and scarring, which can lead to impaired function.
A recent study published in Hepatology suggests that using nitric oxide during liver reperfusion can protect transplanted livers from cell death, improving survival rates. Researchers found that nitric oxide blocks mitochondrial damage, a key factor in organ rejection and failure.
The value of screening varies by condition, and it can both identify treatable conditions and subject patients to invasive evaluations. Researchers recommend carefully considering each condition's worthiness and exploring prospective studies on screening efficacy.
A study found that treating cirrhotic patients with synbiotics or fermentable fiber can alter the gut flora, lowering ammonia levels and improving clinical signs of brain and liver dysfunction. The treatments were effective in reversing minimal hepatic encephalopathy in 50% of patients, compared to 13% in the placebo group.
A substantial majority of people who purchased Prilosec OTC complied very well with the label instructions. The study found that frequent heartburn sufferers increased consultation with their physicians after using the medication.
Researchers discovered that growth hormone activates the Foxm1b gene, a critical regulator of tissue repair and regeneration. The study suggests that declining growth hormone levels in older adults may contribute to reduced healing capacity.
A new investigational vaccine to prevent hepatitis C has been tested in humans for the first time, offering a promising breakthrough against the deadly virus. The study aimed to assess the safety and effectiveness of three different strengths of the Chiron Corporation's vaccine.
Liver cancer patients who undergo transplantation show improved five-year survival rates, increasing steadily from 25.3% to 61.1% over the past two decades. Regular screening of patients with cirrhosis is essential for early detection and optimal outcomes.
A study of nearly 2,000 patients found that heavy alcohol consumption was associated with a higher risk of colorectal cancer. Patients with significant spirits intake may benefit from more intensive screening, according to the American College of Gastroenterology.
Studies link fructose intolerance to IBS symptoms; patients with diet modifications show improved symptoms. Fat consumption is also linked to gastrointestinal disorders, according to a new study.
A new clinical trial led by Duke University aims to compare the efficacy of two pegylated interferon treatments for hepatitis C virus. The IDEAL trial will enroll 2,880 patients and determine which treatment results in a sustained viral response in the largest proportion of patients.
Cedars-Sinai physicians advocate for pre-transplant liver biopsies in living donor liver transplants to detect chronic hepatitis, severe fat in the liver, and other complications that may go unnoticed through routine screenings. The analysis found that only 27% of donors had healthy livers without biopsy results.
A new study found that alcohol consumption increases the activity of a protein that causes the hepatitis C virus to replicate, leading to liver disease. The study also discovered that alcohol interferes with antiviral treatment, such as interferon-alpha, which is currently the only licensed treatment for the infection.
Research found that alcohol consumption increases hepatitis C virus replication by upregulating nuclear factor kappa B, a key cellular regulator of immune pathways. Alcohol also inhibits the anti-HCV effect of interferon-alpha therapy. Treatment with naltrexone abolishes alcohol actions.
A study published in Proceedings of the National Academy of Sciences found a relationship between insulysin and Alzheimer's disease. The researchers discovered that even partial decreases in insulysin activity raised amyloid-beta peptide levels in the brain, increasing the risk of Alzheimer's.
The University of Washington has established a $9 million center to study the underlying causes of hepatitis-induced liver disease. The center brings together experts in viral hepatitis, liver disease, and transplantation to investigate gene and protein expression in liver cells.
A groundbreaking study by Dr. Jorge Bezerra at Cincinnati Children's Hospital Medical Center has identified a genetic underpinning to biliary atresia, the most common reason for liver transplant in children. The discovery points to a potential role of cytokines in driving an inflammatory response against the body's own tissues.
Two studies found significant relationships between GERD, peptic ulcer disease, and hiatal hernia with insomnia and excessive daytime sleepiness. Researchers measured sleep quality using the Pittsburgh Sleep Quality Index exam and objective measures like polysomnography.
A new study found that a combination of peginterferon alfa-2a and ribavirin can offer superior efficacy without increasing common side effects, particularly in patients infected with hepatitis C genotype 1. The treatment approach showed a higher sustained response rate compared to standard therapy.
The VIRAHEP-C clinical trial investigates the effectiveness of combination therapy for chronic hepatitis C, with a focus on racial disparities. Researchers hope to determine factors associated with sustained virological response rates in African-American patients, who are disproportionately affected by the disease.
A combination treatment of Pegasys and ribavirin has shown an unprecedented 61% sustained virologic response rate, the highest ever recorded. The treatment regimen should be based on hepatitis C virus genotype rather than traditional weight-based methodology.
Researchers found no statistical difference between sulindac and placebo groups in preventing polyp development or colon cancer, contradicting previous evidence. Sulindac may be ineffective at preventing polyps in newly diagnosed FAP patients, suggesting a need for alternative treatments.
A Hopkins-led study found that African Americans and Asians have poorer graft rejection and survival rates after liver transplantation compared to white Americans and Hispanics. The study's lead author suggests that more research is needed to determine the causes of these disparities, with preliminary data suggesting socioeconomic fact...
The NIH/Office of the Director's panel endorses ERCP for diagnosing suspected ampullary cancers and treating conditions like symptomatic gallstone disease, but emphasizes caution due to potential complications such as pancreatitis.
Researchers find functional liver tissue in human patients, solving organ shortages and rejection issues. The discovery also enables the growth of artificial livers and targets gene therapy for inherited liver diseases.
Researchers discovered that bone marrow-derived stem cells can generate mature liver cells in humans. This groundbreaking finding has the potential to revolutionize treatment options for liver damage and disease.
The American Liver Foundation will honor Dr. John M. Vierling for his significant advances in understanding autoimmune and alloimmune liver diseases, as well as Dr. Andrew J. Conrad for his impact on chronic viral infections diagnosis and management. The foundation's recognition dinner will take place on February 11.
A new study suggests that the US may soon experience an increase in hepatitis C-related carcinoma cases due to a time difference in the spread of the virus. The study found that the incidence of hepatitis C is similar in Japan and the US, but the incidence of related heptacellular carcinoma (HCC) is eight times higher in Japan.
The American Association for the Study of Liver Diseases (AASLD) will present over 1,000 presentations on liver-related diseases, including new findings on using alcohol to repair damaged livers and the impact of race on response to anti-viral therapy in chronic Hepatitis C patients. The meeting aims to advance the science and practice...